Searching the Crystal Ball for Tailored GLP-1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes/Metabolism Research and Reviews Pub Date : 2024-12-14 DOI:10.1002/dmrr.70017

Asia Saturnino, Ernesto Maddaloni, Simona Zampetti, Raffaella Buzzetti

{"title":"Searching the Crystal Ball for Tailored GLP-1 Receptor Agonists Treatment in Type 2 Diabetes and Obesity","authors":"Asia Saturnino, Ernesto Maddaloni, Simona Zampetti, Raffaella Buzzetti","doi":"10.1002/dmrr.70017","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Glucagon-like peptide 1 receptor agonists (RA) are novel agents used in the management of type 2 diabetes (T2D) and obesity. Although highly effective, the response to treatment may vary significantly among patients.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>This perspective review aims to summarise the current knowledge about markers of poor or good response to GLP-1 RA, highlighting the possibility of tailoring treatment strategies and reducing costs associated with T2D and obesity treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A comprehensive literature search was conducted using PubMed, NCBI, and Scopus databases, focussing on studies published between 2016 and 2024 that evaluated factors influencing treatment outcomes with GLP-1 RA.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Several markers, including baseline HbA1c levels, ghrelin and glucose-dependent insulinotropic polypeptide (GIP) levels, specific gut microbiome composition, b-cell function, and genetic markers, were identified as factors associated with treatment response.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Understanding predictive markers of response to therapy can enhance precision-based medicine for the selection of patients eligible for GLP-1 RA, improving clinical outcomes and optimising diabetes management.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 1","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70017","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70017","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Glucagon-like peptide 1 receptor agonists (RA) are novel agents used in the management of type 2 diabetes (T2D) and obesity. Although highly effective, the response to treatment may vary significantly among patients.

Objective

This perspective review aims to summarise the current knowledge about markers of poor or good response to GLP-1 RA, highlighting the possibility of tailoring treatment strategies and reducing costs associated with T2D and obesity treatment.

Methods

A comprehensive literature search was conducted using PubMed, NCBI, and Scopus databases, focussing on studies published between 2016 and 2024 that evaluated factors influencing treatment outcomes with GLP-1 RA.

Results

Several markers, including baseline HbA1c levels, ghrelin and glucose-dependent insulinotropic polypeptide (GIP) levels, specific gut microbiome composition, b-cell function, and genetic markers, were identified as factors associated with treatment response.

Conclusion

Understanding predictive markers of response to therapy can enhance precision-based medicine for the selection of patients eligible for GLP-1 RA, improving clinical outcomes and optimising diabetes management.

Abstract Image

查看原文本刊更多论文

寻找水晶球，为 2 型糖尿病和肥胖症患者量身定制 GLP-1 受体激动剂治疗方案。

背景：胰高血糖素样肽1受体激动剂（Glucagon-like peptide 1 receptor agonists， RA）是用于治疗2型糖尿病（T2D）和肥胖的新型药物。虽然非常有效，但对治疗的反应可能在患者之间差异很大。目的：这篇前瞻性综述旨在总结目前关于GLP-1 RA不良或良好反应标志物的知识，强调定制治疗策略和降低与T2D和肥胖治疗相关的成本的可能性。方法：使用PubMed、NCBI和Scopus数据库进行综合文献检索，重点检索2016年至2024年间发表的评估GLP-1 RA治疗结果影响因素的研究。结果：几种标志物，包括基线HbA1c水平、胃饥饿素和葡萄糖依赖性胰岛素多肽（GIP）水平、特定肠道微生物组组成、b细胞功能和遗传标志物，被确定为与治疗反应相关的因素。结论：了解治疗反应的预测标志物可以提高GLP-1 RA患者的精准医学选择，改善临床结果，优化糖尿病管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢

CiteScore

17.20

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.